Charlie's Holdings (CHUC)

Overall impact
B (71)

Commentary

Charlie's Holdings is a strong overall performer. With a 'B' rating of 70.8 for overall impact (83rd percentile compared to all companies), Charlie's Holdings ranks 51st out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 47 others, and ahead of Evolus, DiaMedica Therapeutics, Centrexion Therapeutics and 100 others. On top material causes for Charlie's Holdings's industry (Pharmaceuticals & Biotech), Charlie's Holdings performs well in Disease Eradication (96.4 score), Reduced Use of tobacco (95.7), Humane Treatment of Animals (89.4) and 4 other causes where it received an 'A' score and performs poorly in Technology Innovation (19.0 score), Reduced Green House Gas Emissions (24.1) and Disaster Readiness and Effective Aid (37.2).
Impact
Cause CHUC
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
35
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ca, United States
Share classes
CHUC
Description
Charlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related and alternative alkaloid vapor products in the United States and internationally. The company offers nicotine-based disposables under the Pacha, PACHAMAMA, and SBX brands; E-liquid products; and nicotine salt products. It sells its products through distributors, specialty retailers, and third-party online resellers. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.
Material causes
Ethos considers the following causes material for Charlie's Holdings, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.